Screener
Perspective Therapeutics CATX Income Statement
| Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | ||
|---|---|---|---|---|---|---|
| $21.54M+29.6% | $21.37M+49.1% | $32.92M+156% | $20.34M+69.1% | $16.62M+79.2% | ||
| $7.8M+1.1% | $6.99M-10.9% | $6.95M-15.7% | $7.73M+10.8% | $7.71M+39.8% | ||
| $29.34M+20.6% | $28.36M+27.9% | $39.88M-11.8% | $28.07M+47.7% | $24.33M+64.5% | ||
| -$29.26M-21.7% | -$28.28M-29.5% | -$39.83M+11.5% | -$27.86M-49.5% | -$24.04M-68.5% | ||
| $2.28M+11.5% | $2.09M-42.8% | $1.55M-43.0% | $1.89M-46.1% | $2.04M-33.1% | ||
| -$26.98M-22.7% | —— | -$38.28M+9.4% | -$25.97M-71.7% | -$22M-96.2% | ||
| -$26.79M-24.7% | -$26.19M-44.1% | -$37.49M+6.7% | -$25.97M-71.7% | -$21.49M-83.6% | ||
| -$0.22+24.1% | -$0.250.0% | -$0.51+16.4% | -$0.35-66.7% | -$0.29-61.1% | ||
| -$28.12M-20.6% | -$27.16M-28.7% | -$38.82M+12.3% | -$27.09M-50.8% | -$23.31M-70.2% | ||
| -$29.26M-21.7% | -$28.28M-29.5% | -$39.83M+11.5% | -$27.86M-49.5% | -$24.04M-68.5% |
FAQ
- Is Perspective Therapeutics profitable?
- Perspective Therapeutics is not currently profitable: it reported a net loss of $116.4M over the trailing twelve months, a -218.4% net margin.
- What are Perspective Therapeutics's profit margins?
- Gross margin is 33.1% and operating margin is -292.7%, with a -218.4% net margin.
- What is Perspective Therapeutics's earnings per share?
- Perspective Therapeutics's diluted EPS over the trailing twelve months is $-1.33.
- Where does Perspective Therapeutics's income statement data come from?
- Every line is extracted from Perspective Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.